Eve Barys/LinkedIn
May 7, 2026, 15:34
Eve Barys: What’s New – Thrombosis in Immune Thrombocytopenia
Eve Barys, Sr. Strategic Account Executive at Wolters Kluwer Health, shared a post on LinkedIn:
“Immune thrombocytopenia (ITP) is generally associated with bleeding, but individuals with ITP can also develop thrombosis.
A study of ITP documented venous thrombosis in about 4 percent of patients.
Features associated with thrombosis included older age, prior thrombosis, secondary ITP, and use of a thrombopoietin receptor agonist.
Management with anticoagulation is appropriate, and some individuals may require more intensive ITP therapies to raise the platelet count and allow for full anticoagulation.”
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support